Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: J Immunol. 2009 Aug 1;183(3):1911–1920. doi: 10.4049/jimmunol.0900796

FIGURE 8.

FIGURE 8

Increase in numbers of CD8+CD25+ T cells in 4T1 tumor-bearing mice after 1DMab therapy. Groups of BALB/c WT mice (n = 4–5) were inoculated s.c. with the mammary carcinoma cell line 4T1 (2 × 105). On days 7 and 11 after tumor inoculation, groups of mice were treated with TriMab (□), 1DMab therapy (▤), or cIg (■). Four days after the second treatment, tumor DLN were harvested and single-cell suspensions were generated. Cells were stained for surface expression of CD8, CD4, and TCR-β (A); CD8, CD62L, and CD25 (B); CD4, CD62L, and CD25 (C); and CD4, CD25, and intracellularly for FOXP3 (D). Cell numbers are represented as the mean ± SEM. Similar results were obtained in two independent experiments. Statistical differences in cell numbers between mice treated with cIg and mice treated with either 1DMab therapy or TriMab (*) or cell numbers between mice treated with 1DMab therapy or TriMab therapy (**) were determined by Mann-Whitney U test (p < 0.05). ns, Not significant.